Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 6Leukemia, Myeloid, Acute 3Neutropenia 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 75Cyclophosphamide 69Busulfan 62Mycophenolic Acid 50Cyclosporine 48Tacrolimus 47Etoposide 43Whole-Body Irradiation 41Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 18Methylprednisolone 17Flow Cytometry 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14aldesleukin 12Gemtuzumab 12Thiotepa 11Bortezomib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Congenital Abnormalities × Amsacrine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡